方法：本研究为回顾性研究，共纳入糖尿病视网膜病变患者32例32眼，所有患者均伴有明显的黄斑水肿，且首次接受玻璃体腔内注射雷珠单抗。观察指标包括：治疗前后中心凹下脉络膜厚度、黄斑区视网膜厚度及最佳矫正视力，观察时间为治疗后3mo。

结果：治疗后3mo，患者的平均最佳矫正视力显著优于治疗前，且黄斑水肿程度及中心凹下脉络膜厚度均显著降低； Spearman秩相关系数分析提示，术后最佳矫正视力与治疗前黄斑区下脉络膜厚度呈正相关(r_s =0.544，P=0.036)。

结论：在糖尿病视网膜病变所致黄斑水肿的治疗中，治疗前黄斑区下脉络膜厚度较厚的患者似乎对治疗更敏感，术后的最佳矫正视力也更好，因此黄斑区下脉络膜厚度可能可以作为评估其预后的新指标。

METHODS: The current study was a retrospective study, which included 32 patients(32 eyes)diagnosed with diabetic retinopathy and macular edema. All the patients were firstly treated with intravitreal injections of ranibizumab. Main outcome measures were included the subfoveal choroidal thickness, central macular thickness and best-corrected visual acuity(BCVA)at preoperation and postoperative visit at 3mo.

RESULTS: After 3 monthly intravitreal injections of ranibizumab, the BCVA was significantly higher than that before therapy and accompanied with significantly reduced thickness of subfoveal choroid and central fovea of macula. Spearman analysis was revealed that a greater baseline subfoveal choroidal thickness was associated with a better BCVA(r_s =0.544, P=0.036).

CONCLUSION: In the therapy of intravitreal injections of ranibizumab on diabetic macular edema, there seems to be a better BCVA in the patients with a greater baseline subfoveal choroidal thickness. Therefore, baseline subfoveal choroidal thickness may be a useful predictor for the therapy of diabetic macular edema.